atezolizumab FDA approval date

The FDA approved atezolizumab on 18 May 2016.

FDA approval date
18 May 2016

Drug identity checked against registry records

Included trials

TrialSponsorPhaseStatusPrimary completion
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCNCT05733611Replimune, Inc.Phase 2Terminated2025-08-18Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2016-05-18DayatezolizumabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761034", "applicant_as_listed_by_fda": "GENENTECH INC", "brand_names": ["TECENTRIQ"], "active_ingredients": ["ATEZOLIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20160518", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026